Skip to main content
SpringerLink
Log in

Apremilast before biologics for psoriasis cost saving

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. assessed as a 75% improvement in Psoriasis Area and Severity Index

Reference

  • Tencer T, et al. Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States. 73rd Annual Meeting of the American Academy of Dermatology : abstr. 1142, 15 Feb 2015. Available from: URL: https://www.aad.org/eposters/view/Abstract.aspx?id=1142

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apremilast before biologics for psoriasis cost saving. PharmacoEcon Outcomes News 726, 8 (2015). https://doi.org/10.1007/s40274-015-2056-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2056-3

Search

Navigation